Literature DB >> 1546552

Lithium treatment: a comparison of once- and twice-daily dosing.

G Abraham1, N Delva, J Waldron, J S Lawson, J Owen.   

Abstract

The effects of once- and twice-daily dosing with lithium carbonate were compared in a non-blind, cross-over study on 20 consecutive patients with mood disorders. Mental status, side effects and target organ function were examined after a minimum of a 1-month treatment with each regimen. Eighteen patients completed the study and 2 withdrew because of side effects. There were no significant differences between the 2 groups on the Hamilton Rating Scale for Depression, the Bech-Rafaelsen Mania Scale, the UKU Side Effects Scale or in serum lithium, electrocardiogram and urine volumes. Most blood tests showed no significant difference between the 2 treatment schedules except for white blood cells, ionized calcium and phosphate concentration. The once-daily regimen was associated with a higher white cell count, increased serum phosphate and elevated serum ionized calcium. We conclude that patients are able to tolerate once-daily dosing with lithium carbonate as well as twice-daily dosing.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1546552     DOI: 10.1111/j.1600-0447.1992.tb01444.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  4 in total

1.  Stratifying Risk for Renal Insufficiency Among Lithium-Treated Patients: An Electronic Health Record Study.

Authors:  Victor M Castro; Ashlee M Roberson; Thomas H McCoy; Anna Wiste; Andrew Cagan; Jordan W Smoller; Jerrold F Rosenbaum; Michael Ostacher; Roy H Perlis
Journal:  Neuropsychopharmacology       Date:  2015-08-21       Impact factor: 7.853

Review 2.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

Review 3.  The Bech-Rafaelsen Mania Scale in clinical trials of therapies for bipolar disorder: a 20-year review of its use as an outcome measure.

Authors:  Per Bech
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

4.  Combination of strategies to initiate clozapine for refractory schizophrenia in a patient with low neutrophil levels.

Authors:  Keisuke Takanobu; Naoki Hashimoto; Shuhei Ishikawa; Ichiro Kusumi
Journal:  BMJ Case Rep       Date:  2022-10-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.